Jefferies provided color on Ariad Pharmaceuticals ARIA. In a research report published today, Jefferies commented on the company's drug ridaforolimus.
In the report, Jefferies states, "Given that there are no established options for 2nd-line endometrial cancer, we
view ridaforolimus represents a potential treatment option. First-line therapy for
endometrial cancer is hormonal therapy (progestin) or plantinum-sentisitve chemotherapy."
At the moment, Jefferies has a Buy rating and a price target of $11 placed on the company's stock. On Friday, Ariad had a difficult trading session, losing 5.51% to close the week at $7.89. Its shares regained some of its Friday's losses in today's pre-market trading, however, rising 1.77% to $8.03.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in